Tao Ji
Cytori Therapeutics (United States)
ORCID: 0000-0003-4522-8888Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 2 papers. Top paper: “FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies”.
Nicholas Iannotti, Martin Gutierrez, David C. Smith, Luis Féliz, Christine Lihou +5 more
Xie-Jun Zhang, Tao Ji, Guo-Dong Huang, Wen-Jian Zheng